Vol. 4 No. 12 (2024)
Reimbursement Reviews

Inclisiran (Leqvio)

decorative image of the issue cover

Published December 19, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses inclisiran (Leqvio), 284 mg in 1.5 mL, solution for subcutaneous injection in prefilled syringe.
  • Indication: As an adjunct to lifestyle changes, including diet, to further reduce low-density-lipoprotein cholesterol (LDL‐C) level in adults with the following conditions who are on a maximally tolerated dose of a statin, with or without other LDL‐C‐lowering therapies:
    • heterozygous familial hypercholesterolemia
    • nonfamilial hypercholesterolemia with atherosclerotic cardiovascular disease.